AR126971A1 - Composiciones y métodos para tratar el síndrome de qt largo - Google Patents
Composiciones y métodos para tratar el síndrome de qt largoInfo
- Publication number
- AR126971A1 AR126971A1 ARP220102385A ARP220102385A AR126971A1 AR 126971 A1 AR126971 A1 AR 126971A1 AR P220102385 A ARP220102385 A AR P220102385A AR P220102385 A ARP220102385 A AR P220102385A AR 126971 A1 AR126971 A1 AR 126971A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody according
- seq
- syndrome
- set forth
- antibody
- Prior art date
Links
- 208000004731 long QT syndrome Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 101001026226 Homo sapiens Potassium voltage-gated channel subfamily KQT member 1 Proteins 0.000 abstract 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000053010 human KCNQ1 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
En el presente documento se proporcionan anticuerpos monoclonales anti-KCNQ1 y su uso en el tratamiento del síndrome de QT largo (LQTS). Reivindicación 1: Un anticuerpo monoclonal aislado o un fragmento de unión al antígeno de este que se une específicamente a KCNQ1 humano, en donde el anticuerpo comprende un conjunto de 6 CDR establecidas en SEQ ID Nº 1 - 6. Reivindicación 2: El anticuerpo de acuerdo con la reivindicación 1, que comprende una secuencia de aminoácidos de la región variable de la cadena liviana establecida en SEQ ID Nº 7. Reivindicación 3: El anticuerpo de acuerdo con la reivindicación 1 o la reivindicación 2, que comprende una secuencia de aminoácidos de la región variable de la cadena pesada establecida en SEQ ID Nº 8. Reivindicación 4: El anticuerpo de acuerdo con la reivindicación 1, en donde el fragmento de unión al antígeno es un fragmento Fab o un scFv. Reivindicación 5: El anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 - 4, que comprende además un dominio constante de la cadena pesada. Reivindicación 6: El anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 - 5, que comprende un dominio constante de la cadena liviana.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240494P | 2021-09-03 | 2021-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126971A1 true AR126971A1 (es) | 2023-12-06 |
Family
ID=83228888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102385A AR126971A1 (es) | 2021-09-03 | 2022-09-02 | Composiciones y métodos para tratar el síndrome de qt largo |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR126971A1 (es) |
| AU (1) | AU2022336625A1 (es) |
| CA (1) | CA3230815A1 (es) |
| TW (1) | TW202323276A (es) |
| WO (1) | WO2023031881A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024050526A1 (en) * | 2022-09-02 | 2024-03-07 | Biomarin Pharmaceutical Inc. | Compositions and methods for treating long qt syndrome |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5780279A (en) | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| US5858657A (en) | 1992-05-15 | 1999-01-12 | Medical Research Council | Methods for producing members of specific binding pairs |
| US5855885A (en) | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| CA2398136A1 (en) | 2000-02-08 | 2001-08-16 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US9345688B2 (en) * | 2013-03-15 | 2016-05-24 | Washington University | KCNQ channels as therapeutic targets |
| US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2022
- 2022-09-02 WO PCT/IB2022/058286 patent/WO2023031881A1/en active Application Filing
- 2022-09-02 AU AU2022336625A patent/AU2022336625A1/en active Pending
- 2022-09-02 AR ARP220102385A patent/AR126971A1/es unknown
- 2022-09-02 CA CA3230815A patent/CA3230815A1/en active Pending
- 2022-09-02 TW TW111133459A patent/TW202323276A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023031881A1 (en) | 2023-03-09 |
| TW202323276A (zh) | 2023-06-16 |
| AU2022336625A1 (en) | 2024-04-11 |
| CA3230815A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| EA202092844A1 (ru) | Анти-интерлейкин-17а антитело, фармацевтическая композиция и их применение | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| RS52332B (en) | HUMAN ANTI-NGF NEUTRAL ANTIBODIES AS SELECTIVE NGF SIGNAL ROUTE INHIBITORS | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| PE20090046A1 (es) | Anticuerpo recombinante humanizado anti-interleuquina 10 | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| PE20230306A1 (es) | Anticuerpos que se dirigen a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| PE20230374A1 (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clasico y neoantigeno y sus metodos de uso | |
| AR126971A1 (es) | Composiciones y métodos para tratar el síndrome de qt largo | |
| PE20231504A1 (es) | Anticuerpos especificos para kras y sus usos | |
| AR110967A1 (es) | Anticuerpos miméticos fgf21 y su uso | |
| CO2022010294A2 (es) | Anticuerpos cd163 o proteinas de union | |
| ZA202205288B (en) | Humanized antibody and method for using the same | |
| AR124558A1 (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-fármaco | |
| MX2022005949A (es) | Anticuerpos anti-ror-2 y metodos de uso. | |
| AR120430A1 (es) | Células car-t dirigidas a epha3 para el tratamiento de tumores | |
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| AR124123A1 (es) | Anticuerpos anti-cd25 | |
| WO2022174103A3 (en) | Monoclonal antibodies specific for human ror1 | |
| WO2022026807A3 (en) | Antibodies targeting sars-cov-2 and uses thereof |